Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial
Related Posts
Hoeper MM, Ewert R, Jansa P, Sirenko Y, Skride A, Balagtas C, Hackley S, Vogt S, Abreu P, Haughie S, Hassan T, Oudiz RJ. Randomized,[...]
Tio MC, Butler J, Zhu X, Obi Y, Yen TE, Kalantar-Zadeh K, Streja E, Dossabhoy NR, Hall ME, Shafi T. Individualized Risk for CKD Progression[...]
Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman[...]